Skip to main content

Table 3 Resolution of symptoms of COVID-19

From: Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Symptoms Time to resolution of symptoms Resolution of symptoms
Treatment (n = 36) Control (n = 36)
Median (95%CI) Median (95%CI) HRa 95%CI p-value
All symptoms 8 (5–10) 8 (7–13) 1.18 (0.68 to 2.05) 0.562
Cough 5 (3–8) 8 (4–8) 1.23 (0.74 to 2.03) 0.427
Runny nose 0 (0–3) 2 (0–5) 1.32 (0.82 to 2.13) 0.251
Sore throat 0 (0–3) 0 (0–3) 1.00 (0.63 to 1.59) 0.997
Smell disturbance 0 (0–0) 0 (0–0) 1.23 (0.76 to 1.99) 0.391
Taste disturbance 0 (0–1) 0 (0–0) 0.96 (0.60 to 1.53) 0.864
Muscle pain 0 (0–1) 0 (0–0) 0.81 (0.50 to 1.31) 0.388
Headache 0 (0–0) 0 (0–0) 1.25 (0.78 to 2.02) 0.354
Fever 0 (0–1) 0 (0–1) 0.90 (0.57 to 1.43) 0.650
Dyspnea 0 (0–0) 0 (0–0) 0.97 (0.61 to 1.54) 0.888
Block nose 0 (0–0) 0 (0–0) 1.08 (0.68 to 1.73) 0.733
Diarrhea 0 (0–0) 0 (0–0) 1.03 (0.65 to 1.65) 0.888
Chest pain 0 (0–0) 0 (0–0) 1.06 (0.66 to 1.69) 0.811
Fatigue 0 (0–0) 0 (0–0) 1.19 (0.73 to 1.92) 0.488
Sneezing 0 (0–0) 0 (0–0) 1.05 (0.66 to 1.67) 0.843
Vomiting 0 (0–0) 0 (0–0) 1.03 (0.65 to 1.64) 0.906
  1. aHazard ratio for resolution of symptoms was estimated by the Cox proportional-hazard model